{
    "clinical_study": {
        "@rank": "78750", 
        "arm_group": [
            {
                "arm_group_label": "ID saline", 
                "arm_group_type": "Placebo Comparator", 
                "description": "ID saline by feeding tube"
            }, 
            {
                "arm_group_label": "ID saline + CDCA (5 mmol/L)", 
                "arm_group_type": "Active Comparator", 
                "description": "CDCA = chenodeoxycholic acid (primary bile acid)"
            }, 
            {
                "arm_group_label": "ID + CDCA (15 mmol/L)", 
                "arm_group_type": "Active Comparator", 
                "description": "CDCA = chenodeoxycholic acid (primary bile acid)"
            }, 
            {
                "arm_group_label": "ID saline + oleanolic acid (1 mmol/L)", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "ID saline + CDCA (5 mmol/L) + oleic acid", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "ID saline + oleic acid (20 mmol/L)", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is do determine the functional significance of the G\n      protein-coupled receptor TGR5 in the secretion of GI satiation peptides by using natural\n      bile acids and oleanolic acid (triterpenoid compound of plant origin) as TGR5 agonists."
        }, 
        "brief_title": "Effect of Bile Acids on the Secretion of Satiation Peptides in Humans", 
        "completion_date": {
            "#text": "May 2012", 
            "@type": "Actual"
        }, 
        "condition": "Echolocation", 
        "detailed_description": {
            "textblock": "TGR5 is expressed in GLP-1-secreting cell lines and L cells from mice; gain- and\n      loss-of-function models suggest a physiological role for TGR5 activation on GLP-1 secretion\n      in rodents. TGR5 signaling showed improved postprandial glucose tolerance in obese mice,\n      associated with marked postprandial GLP-1 release and insulin secretion. In contrast,\n      TGR5-/- mice exhibited reduced glucose tolerance. In animals, TGR5 activation has been shown\n      for natural bile acids (BAs) and triterpenoid compounds of plant origin, such as oleanolic\n      acid (OA), suggesting a role for postprandial BAs in modulating nutrient-induced GLP-1\n      secretion. We therefore hypothesized that intraduodenal (ID) perfusions of TGR5 agonists\n      (BAs and OA) stimulate the secretion of GLP-1 with respective changes in the glucose\n      metabolism of healthy humans."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy subjects\n\n          -  BMI of 19.0-24.5\n\n          -  Age 18-40\n\n          -  Stable body weight for at least 3 months\n\n        Exclusion Criteria:\n\n          -  Smoking\n\n          -  Substance abuse\n\n          -  Regular intake of medication\n\n          -  Medical of psychiatric illness\n\n          -  Gastrointestinal disorders or food allergies"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 24, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01674946", 
            "org_study_id": "EKBB 140/11"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ID saline", 
                    "ID saline + CDCA (5 mmol/L)", 
                    "ID + CDCA (15 mmol/L)", 
                    "ID saline + oleanolic acid (1 mmol/L)", 
                    "ID saline + CDCA (5 mmol/L) + oleic acid", 
                    "ID saline + oleic acid (20 mmol/L)"
                ], 
                "description": "intraduodenal perfusion", 
                "intervention_name": "saline", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": [
                    "ID saline + CDCA (5 mmol/L)", 
                    "ID + CDCA (15 mmol/L)", 
                    "ID saline + CDCA (5 mmol/L) + oleic acid"
                ], 
                "description": "intraduodenal perfusion", 
                "intervention_name": "bile acid (CDCA, chenodeoxycholic acid)", 
                "intervention_type": "Other", 
                "other_name": "primary bile acid"
            }, 
            {
                "arm_group_label": "ID saline + oleanolic acid (1 mmol/L)", 
                "description": "intraduodenal perfusion", 
                "intervention_name": "oleanolic acid", 
                "intervention_type": "Other", 
                "other_name": "triterpenoid compound of plant origin"
            }, 
            {
                "arm_group_label": [
                    "ID saline + CDCA (5 mmol/L) + oleic acid", 
                    "ID saline + oleic acid (20 mmol/L)"
                ], 
                "description": "intraduodenal perfusion", 
                "intervention_name": "oleic acid", 
                "intervention_type": "Dietary Supplement", 
                "other_name": "fatty acid"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Bile Acids and Salts", 
                "Chenodeoxycholic Acid"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "GI-physiology", 
            "CDCA", 
            "bile acids", 
            "TGR5", 
            "satiation peptides"
        ], 
        "lastchanged_date": "August 24, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "Basel", 
                    "country": "Switzerland", 
                    "zip": "4031"
                }, 
                "name": "University Hospital Basel, Phase 1 Research Unit"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "6", 
        "official_title": "Effect of Intraduodenal Perfusion of Bile Acids on the Secretion of Gastrointestinal Satiation Peptides in Healthy Male Volunteers", 
        "overall_official": {
            "affiliation": "University Hospital Basel, Phase 1 Research Unit, Basel Switzerland", 
            "last_name": "Christoph Beglinger, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Assessment of plasma GLP-1, PYY and CCK release to BA and OA stimulation", 
            "measure": "Gastrointestinal satiation peptide secretion", 
            "safety_issue": "No", 
            "time_frame": "3 hours blood sampling"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01674946"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Assessment of serum bile acids levels to BA and OA stimulation", 
                "measure": "Serum bile acids", 
                "safety_issue": "No", 
                "time_frame": "3 hours blood sampling"
            }, 
            {
                "description": "Assessment of the following appetite perceptions markers: feelings of hunger, feelings of prospective food consumption, feelings of fullness and feelings of satiety using validated visual analogue scales", 
                "measure": "Appetite perceptions during 3 hours using visual analogue scales", 
                "safety_issue": "No", 
                "time_frame": "3 hours"
            }, 
            {
                "description": "Assessment of plasma glucose and insulin levels to BA and OA stimulation", 
                "measure": "Glucose and insulin secretion", 
                "safety_issue": "No", 
                "time_frame": "3 hours blood sampling"
            }
        ], 
        "source": "University Hospital, Basel, Switzerland", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University Hospital, Basel, Switzerland", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}